Newark, Delaware – GenPro, a precision heath solutions company pioneering the discovery and commercialization of a new class of biomarkers, epigenetic biomarkers, from blood samples and their translation into actionable assays and information to enable biopharma companies focused on immuno-oncology to dramatically improve the selection of patients into their clinical trials who will respond to their new immuno-therapeutics today announced that its Chairman, CEO and Co-founder, Jeb Connor, will present at the Biotech Showcase ™ 2018 Conference in San Francisco, January 8–10.
Mr. Connor’s presentation will describe the Company, its strategy, its proprietary cloud-based analytics and machine learning platform’s novel EpiMarker discovery capabilities, illustrate accomplishments through use-cases, and provide growth projections and related information in support of a $6M Series A private placement equity round that it is raising.
The presentation will take place on Tuesday, January 9th at 9AM PT at the Franciscan Room (Ballroom Level) of the Hilton San Francisco Union Square located at 333 O’Farrell Street, San Francisco, CA (United States).
GenPro (www.genprollc.com) is a precision health solutions company serving the biopharma/biotech industry, clinical research institutions, and ultimately clinicians and patients. Powered by a proprietary cloud-based analytics and machine learning platform, GenPro is leading the discovery and commercialization of a powerful new class of clinically actionable gene methylation biomarkers, or EpiMarkers, from blood samples and translating them into high-throughput, low-cost precision tests that identify patients who will respond to specific drug therapies with a much higher degree of likelihood than can be achieved by current approaches. Today, GenPro is primarily applying its transformational capabilities through collaborations with biopharma companies in immuno-oncology to rapidly discover novel EpiMarkers and assays for patient selection into clinical trials that are matched to their specific drugs to enable dramatic improvements in clinical trial outcomes, economics and time to market. This includes the concurrent development of the assay into a companion diagnostic while also illuminating informative new molecular insights into involved genes, pathways and mechanisms of actions, all of which genomic analysis or genomic biomarkers do not provide.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Genome Profiling will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Contacts: For more information via email GenPro at: email@example.com